Literature DB >> 17556366

Differential association of hemoglobin with proinflammatory high density lipoproteins in atherogenic/hyperlipidemic mice. A novel biomarker of atherosclerosis.

Junji Watanabe1, Katherine J Chou, James C Liao, Yunan Miao, Hsiang-Hui Meng, Helen Ge, Victor Grijalva, Susan Hama, Kathy Kozak, Georgette Buga, Julian P Whitelegge, Terry D Lee, Robin Farias-Eisner, Mohamad Navab, Alan M Fogelman, Srinivasa T Reddy.   

Abstract

Studies in both mice and humans suggest that the anti- or proinflammatory nature of high density lipoprotein (HDL) may be a more sensitive predictor of risk for coronary heart disease events. In this study, we report the identification and characterization of two proteins (m/z 14,900 and 15,600) that are most dramatically associated with HDL in mouse models of atherosclerosis. Mass spectral analyses of proinflammatory HDL identified the two peaks to be hemoglobin (Hb) alpha and beta chains, respectively, with no apparent post-translational modification. Biochemical analysis confirmed the differential association of Hb with HDL from hyperlipidemic mice. We further show that HDL-associated Hb is predominantly in the oxyHb form with distinct physical and chemical properties. Furthermore oxyHb-containing proinflammatory HDL potently consumed nitric oxide and contracted arterial vessels ex vivo. Moreover Hb also was found differentially associated with HDL from coronary heart disease patients compared with healthy controls. Our data suggest that Hb contributes to the proinflammatory nature of HDL in mouse and human models of atherosclerosis and may serve as a novel biomarker for atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17556366     DOI: 10.1074/jbc.M702163200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  L-4F differentially alters plasma levels of oxidized fatty acids resulting in more anti-inflammatory HDL in mice.

Authors:  Satoshi Imaizumi; Victor Grijalva; Mohamad Navab; Brian J Van Lenten; Alan C Wagner; G M Anantharamiah; Alan M Fogelman; Srinivasa T Reddy
Journal:  Drug Metab Lett       Date:  2010-08

Review 2.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

Review 3.  Dysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteins.

Authors:  Satoshi Imaizumi; Mohamad Navab; Cecilia Morgantini; Christina Charles-Schoeman; Feng Su; Feng Gao; Murray Kwon; Ekambaram Ganapathy; David Meriwether; Robin Farias-Eisner; Alan M Fogelman; Srinivasa T Reddy
Journal:  Circ J       Date:  2011-05-28       Impact factor: 2.993

Review 4.  Haptoglobin genotype and its role in diabetic cardiovascular disease.

Authors:  Tina Costacou; Andrew P Levy
Journal:  J Cardiovasc Transl Res       Date:  2012-03-24       Impact factor: 4.132

Review 5.  Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease.

Authors:  Rai Ajit K Srivastava
Journal:  Mol Cell Biochem       Date:  2017-08-21       Impact factor: 3.396

Review 6.  HDL dysfunction in diabetes: causes and possible treatments.

Authors:  Dan Farbstein; Andrew P Levy
Journal:  Expert Rev Cardiovasc Ther       Date:  2012-03

7.  Serum free hemoglobin as a novel potential biomarker for acute ischemic stroke.

Authors:  Poyin Huang; Li-Hua Lo; Yin-Chun Chen; Ruey-Tay Lin; Jentaie Shiea; Ching-Kuan Liu
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

Review 8.  Role of hemoglobin/heme scavenger protein hemopexin in atherosclerosis and inflammatory diseases.

Authors:  Niyati U Mehta; Srinivasa T Reddy
Journal:  Curr Opin Lipidol       Date:  2015-10       Impact factor: 4.776

Review 9.  Why is HDL functionally deficient in type 2 diabetes?

Authors:  Anatol Kontush; M John Chapman
Journal:  Curr Diab Rep       Date:  2008-02       Impact factor: 4.810

Review 10.  HDL as a biomarker, potential therapeutic target, and therapy.

Authors:  Mohamad Navab; G M Anantharamaiah; Srinivasa T Reddy; Brian J Van Lenten; Alan M Fogelman
Journal:  Diabetes       Date:  2009-12       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.